Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN060 vs Adalimumab in Healthy Adults
NCT03254810Phase 1Completed
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Sep 2017
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adalimumab biosimilar syn060 in rheumatoid arthritis (RA) (3 arms), sponsored by Xingmeng Biopharmaceutical. Primary endpoints: Area under the concentration-time curve from time zero to the last non-zero concentration at 85 days, Area under the concentration-time curve from time zero to infinity at 85 days and 7 more. Started Sep 2017; status: completed.
02
Drugs
adalimumab biosimilar syn060
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03254810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254810.